The latest price target for Amphastar Pharma (NASDAQ:AMPH) was reported by Wells Fargo on May 14, 2026. The analyst firm set a price target for $19.00 expecting AMPH to rise to within 12 months (a possible 7.34% upside). 13 analyst firms have reported ratings in the last year.

The latest analyst rating for Amphastar Pharma (NASDAQ:AMPH) was provided by Wells Fargo, and Amphastar Pharma downgraded their equal-weight rating.

The last upgrade for Amphastar Pharmaceuticals Inc happened on August 12, 2025 when Needham raised their price target to $36. Needham previously had a hold for Amphastar Pharmaceuticals Inc.

The last downgrade for Amphastar Pharmaceuticals Inc happened on May 14, 2026 when Wells Fargo changed their price target from $30 to $19 for Amphastar Pharmaceuticals Inc.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Amphastar Pharma, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Amphastar Pharma was filed on May 14, 2026 so you should expect the next rating to be made available sometime around May 14, 2027.

While ratings are subjective and will change, the latest Amphastar Pharma (AMPH) rating was a downgraded with a price target of $30.00 to $19.00. The current price Amphastar Pharma (AMPH) is trading at is $17.70, which is out of the analyst’s predicted range.